Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Typhoid Fever Vaccine Market by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine, Others), by Route of Administration (Oral, Injection) and by End User (Hospitals and Clinics, Specialty Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12362

Pages: NA

Charts: NA

Tables: NA

Typhoid fever is a bacterial infection caused by the bacterium Salmonella typhi. The symptoms of a typhoid infection include persistent high fever, headache, diarrhea, weakness, and loss of appetite. This infection can spread throughout the body and affect many organs. In addition, without prompt treatment, typhoid fever can also cause serious complications which can lead to the patient's death. Hence, a typhoid vaccine has become crucial as it helps prevent typhoid fever in humans. There are two common types of typhoid vaccines which include inactivated (killed) typhoid vaccine and attenuated (weakened) typhoid vaccine.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in December, 2019. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since its outbreak,, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

However, with COVID-19, the supply chain of the raw materials required to manufacture vaccines for typhoid fever has been disrupted in many countries. In addition, the market growth of pharmaceuticals is on decline as the manufacturers of drugs and vaccines have slowed down their production because of the pandemic. This, in turn, is expected to have a significant impact on the typhoid fever vaccine market.

Top Impacting Factors

There has been increased research on typhoid vaccines in emerging markets such as Europe and Asia-Pacific. This factor is acting as a driver for the typhoid fever vaccine market.

In addition, the governments of many developed nations are investing in manufacturing typhoid vaccines. This is also leading to the development of better and highly advanced typhoid fever vaccines.

The number of typhoid cases is highly prevalent in many developing nations. With this, there is also a high mortality rate associated with typhoid which has increased the demand for typhoid vaccines. Hence, this demand is also helping in the growth of the typhoid fever vaccine market.

However, the less availability of these vaccines in remote areas and strict regulations associated with the launch of new vaccines are some of the factors that hinder the growth of the typhoid fever vaccine market.

Key Market Trends

In 2019, the highest share of the typhoid fever vaccine market was accounted for by the capsular polysaccharide segment. The growth of this particular typhoid fever vaccine segment is attributed to its effectiveness in preventing typhoid infections.

North America holds the major share of the market owing to the increase in awareness among citizens which has led to the demand for typhoid vaccines for infants, children as well as adults. The easy availability of vaccines in the U.S. has also fueled the market growth in this region.

Furthermore, the typhoid fever vaccine market in the Asia-Pacific is expected to grow at a significant rate due to government initiatives being taken for immunization against typhoid fever and a large population base, especially in India and China.

In Latin America, Brazil is likely to be one of the prominent players in the typhoid fever vaccine market due to developing healthcare infrastructure and investments by major key players in the country who have established vaccine manufacturing units in the nation.

Key Benefits of the Report

  • This study presents the analytical depiction of the typhoid fever vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the typhoid fever vaccinemarket share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the typhoid fever vaccine market.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Typhoid Fever Vaccine Report

  • Which are the leading players active in the typhoid fever vaccine market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the typhoid fever vaccine market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is a typhoid fever vaccine?
  • What are the current and predicted trends of the market?

 Key Market Segments

  • By Vaccine Type
    • Live Attenuated Vaccine
    • Capsular Polysaccharide Vaccine
    • Conjugate Vaccine
    • Others
  • By Route of Administration
    • Oral
    • Injection
  • By End User
    • Hospitals and Clinics
    • Specialty Centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Scandinavian Biopharma
  • Prokarium Ltd.
  • PT Bio Farma
  • China National Biotec Group
  • Shanghai institute of biological products co., ltd.
  • Bharat Biotech
  • GlaxoSmithKline
  • Paxvax Inc.
  • BIO-MED
  • Sanofi

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: TYPHOID FEVER VACCINE MARKET, BY VACCINE TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Vaccine Type

    • 4.2. Live Attenuated Vaccine

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Capsular Polysaccharide Vaccine

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Conjugate Vaccine

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: TYPHOID FEVER VACCINE MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Injection

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: TYPHOID FEVER VACCINE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals And Clinics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Specialty Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: TYPHOID FEVER VACCINE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Vaccine Type

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Typhoid Fever Vaccine Market

        • 7.2.6.1. Market Size and Forecast, By Vaccine Type
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Typhoid Fever Vaccine Market

        • 7.2.7.1. Market Size and Forecast, By Vaccine Type
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Typhoid Fever Vaccine Market

        • 7.2.8.1. Market Size and Forecast, By Vaccine Type
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Vaccine Type

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Typhoid Fever Vaccine Market

        • 7.3.6.1. Market Size and Forecast, By Vaccine Type
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Typhoid Fever Vaccine Market

        • 7.3.7.1. Market Size and Forecast, By Vaccine Type
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Typhoid Fever Vaccine Market

        • 7.3.8.1. Market Size and Forecast, By Vaccine Type
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Typhoid Fever Vaccine Market

        • 7.3.9.1. Market Size and Forecast, By Vaccine Type
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Typhoid Fever Vaccine Market

        • 7.3.10.1. Market Size and Forecast, By Vaccine Type
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Typhoid Fever Vaccine Market

        • 7.3.11.1. Market Size and Forecast, By Vaccine Type
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Typhoid Fever Vaccine Market

        • 7.3.12.1. Market Size and Forecast, By Vaccine Type
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Vaccine Type

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Typhoid Fever Vaccine Market

        • 7.4.6.1. Market Size and Forecast, By Vaccine Type
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Typhoid Fever Vaccine Market

        • 7.4.7.1. Market Size and Forecast, By Vaccine Type
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Typhoid Fever Vaccine Market

        • 7.4.8.1. Market Size and Forecast, By Vaccine Type
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Typhoid Fever Vaccine Market

        • 7.4.9.1. Market Size and Forecast, By Vaccine Type
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Typhoid Fever Vaccine Market

        • 7.4.10.1. Market Size and Forecast, By Vaccine Type
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Typhoid Fever Vaccine Market

        • 7.4.11.1. Market Size and Forecast, By Vaccine Type
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Typhoid Fever Vaccine Market

        • 7.4.12.1. Market Size and Forecast, By Vaccine Type
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Typhoid Fever Vaccine Market

        • 7.4.13.1. Market Size and Forecast, By Vaccine Type
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Typhoid Fever Vaccine Market

        • 7.4.14.1. Market Size and Forecast, By Vaccine Type
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Vaccine Type

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Typhoid Fever Vaccine Market

        • 7.5.6.1. Market Size and Forecast, By Vaccine Type
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Typhoid Fever Vaccine Market

        • 7.5.7.1. Market Size and Forecast, By Vaccine Type
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Typhoid Fever Vaccine Market

        • 7.5.8.1. Market Size and Forecast, By Vaccine Type
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Typhoid Fever Vaccine Market

        • 7.5.9.1. Market Size and Forecast, By Vaccine Type
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Typhoid Fever Vaccine Market

        • 7.5.10.1. Market Size and Forecast, By Vaccine Type
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Typhoid Fever Vaccine Market

        • 7.5.11.1. Market Size and Forecast, By Vaccine Type
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Shanghai Institute Of Biological Products Co., Ltd.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Bharat Biotech

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Sanofi

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. GlaxoSmithKline

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Paxvax Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. PT Bio Farma

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. BIO-MED

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Prokarium Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Scandinavian Biopharma

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. China National Biotec Group

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL TYPHOID FEVER VACCINE MARKET, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL TYPHOID FEVER VACCINE MARKET FOR LIVE ATTENUATED VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL TYPHOID FEVER VACCINE MARKET FOR CAPSULAR POLYSACCHARIDE VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL TYPHOID FEVER VACCINE MARKET FOR CONJUGATE VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL TYPHOID FEVER VACCINE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL TYPHOID FEVER VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL TYPHOID FEVER VACCINE MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL TYPHOID FEVER VACCINE MARKET FOR INJECTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL TYPHOID FEVER VACCINE MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL TYPHOID FEVER VACCINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL TYPHOID FEVER VACCINE MARKET FOR SPECIALTY CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL TYPHOID FEVER VACCINE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL TYPHOID FEVER VACCINE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA TYPHOID FEVER VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. U.S. TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 20. U.S. TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CANADA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 22. CANADA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 23. CANADA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE TYPHOID FEVER VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ITALY TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ITALY TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 39. ITALY TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. UK TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 44. UK TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 45. UK TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC TYPHOID FEVER VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. CHINA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 57. CHINA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 58. CHINA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. INDIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 63. INDIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 64. INDIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA TYPHOID FEVER VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. UAE TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 97. UAE TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 98. UAE TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA TYPHOID FEVER VACCINE, BY VACCINE TYPE, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA TYPHOID FEVER VACCINE, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA TYPHOID FEVER VACCINE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: KEY EXECUTIVES
  • TABLE 106. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT
  • TABLE 107. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: OPERATING SEGMENTS
  • TABLE 108. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 109. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BHARAT BIOTECH: KEY EXECUTIVES
  • TABLE 111. BHARAT BIOTECH: COMPANY SNAPSHOT
  • TABLE 112. BHARAT BIOTECH: OPERATING SEGMENTS
  • TABLE 113. BHARAT BIOTECH: PRODUCT PORTFOLIO
  • TABLE 114. BHARAT BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. SANOFI: KEY EXECUTIVES
  • TABLE 116. SANOFI: COMPANY SNAPSHOT
  • TABLE 117. SANOFI: OPERATING SEGMENTS
  • TABLE 118. SANOFI: PRODUCT PORTFOLIO
  • TABLE 119. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 121. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 122. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 123. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 124. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. PAXVAX INC.: KEY EXECUTIVES
  • TABLE 126. PAXVAX INC.: COMPANY SNAPSHOT
  • TABLE 127. PAXVAX INC.: OPERATING SEGMENTS
  • TABLE 128. PAXVAX INC.: PRODUCT PORTFOLIO
  • TABLE 129. PAXVAX INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. PT BIO FARMA: KEY EXECUTIVES
  • TABLE 131. PT BIO FARMA: COMPANY SNAPSHOT
  • TABLE 132. PT BIO FARMA: OPERATING SEGMENTS
  • TABLE 133. PT BIO FARMA: PRODUCT PORTFOLIO
  • TABLE 134. PT BIO FARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. BIO-MED: KEY EXECUTIVES
  • TABLE 136. BIO-MED: COMPANY SNAPSHOT
  • TABLE 137. BIO-MED: OPERATING SEGMENTS
  • TABLE 138. BIO-MED: PRODUCT PORTFOLIO
  • TABLE 139. BIO-MED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. PROKARIUM LTD.: KEY EXECUTIVES
  • TABLE 141. PROKARIUM LTD.: COMPANY SNAPSHOT
  • TABLE 142. PROKARIUM LTD.: OPERATING SEGMENTS
  • TABLE 143. PROKARIUM LTD.: PRODUCT PORTFOLIO
  • TABLE 144. PROKARIUM LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. SCANDINAVIAN BIOPHARMA: KEY EXECUTIVES
  • TABLE 146. SCANDINAVIAN BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 147. SCANDINAVIAN BIOPHARMA: OPERATING SEGMENTS
  • TABLE 148. SCANDINAVIAN BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 149. SCANDINAVIAN BIOPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. CHINA NATIONAL BIOTEC GROUP: KEY EXECUTIVES
  • TABLE 151. CHINA NATIONAL BIOTEC GROUP: COMPANY SNAPSHOT
  • TABLE 152. CHINA NATIONAL BIOTEC GROUP: OPERATING SEGMENTS
  • TABLE 153. CHINA NATIONAL BIOTEC GROUP: PRODUCT PORTFOLIO
  • TABLE 154. CHINA NATIONAL BIOTEC GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPHOID FEVER VACCINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL TYPHOID FEVER VACCINE MARKET
  • FIGURE 3. SEGMENTATION TYPHOID FEVER VACCINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN TYPHOID FEVER VACCINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTYPHOID FEVER VACCINE MARKET
  • FIGURE 11. TYPHOID FEVER VACCINE MARKET SEGMENTATION, BY BY VACCINE TYPE
  • FIGURE 12. TYPHOID FEVER VACCINE MARKET FOR LIVE ATTENUATED VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. TYPHOID FEVER VACCINE MARKET FOR CAPSULAR POLYSACCHARIDE VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. TYPHOID FEVER VACCINE MARKET FOR CONJUGATE VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. TYPHOID FEVER VACCINE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. TYPHOID FEVER VACCINE MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 17. TYPHOID FEVER VACCINE MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TYPHOID FEVER VACCINE MARKET FOR INJECTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TYPHOID FEVER VACCINE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. TYPHOID FEVER VACCINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TYPHOID FEVER VACCINE MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TYPHOID FEVER VACCINE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: TYPHOID FEVER VACCINE MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. BHARAT BIOTECH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. BHARAT BIOTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. BHARAT BIOTECH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. GLAXOSMITHKLINE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. PAXVAX INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. PAXVAX INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. PAXVAX INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. PT BIO FARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. PT BIO FARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. PT BIO FARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. BIO-MED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. BIO-MED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. BIO-MED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. PROKARIUM LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. PROKARIUM LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. PROKARIUM LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. SCANDINAVIAN BIOPHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. SCANDINAVIAN BIOPHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. SCANDINAVIAN BIOPHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. CHINA NATIONAL BIOTEC GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. CHINA NATIONAL BIOTEC GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. CHINA NATIONAL BIOTEC GROUP: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Typhoid Fever Vaccine Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved